Adipose-derived stem cells attenuate pulmonary arterial hypertension and ameliorate pulmonary arterial remodeling in monocrotaline-induced pulmonary hypertensive rats
Abstract We investigated the effect of adipose-derived stem cells (ADSCs) transplantation effects on structural remodeling and pulmonary artery pressure in monocrotaline (MCT)-induced pulmonary hypertensive rats. In the first experiment, 32 male Sprague-Dawley (SD) rats were randomly divided into four groups (n = 8/group): 3 ADSCs treated groups and normal control (Ctrl). ADSCs were administered through the left jugular vein at 105, 106 and 107 cells, respectively, and a cell density of 106cells/ml was shown to be optimal. The GFP-tagged ADSCs were identified in the lungs and differentiated into endothelial-like cells. In the second experiment, 96 male SD rats were randomly divided into three groups (n = 32/group): Ctrl, MCT-induced pulmonary arterial hypertension (PAH), and PAH treated with ADSCs (ADSCs). Two weeks post-MCT administration, the ADSCs group received 1 × 106 ADSCs via the external jugular vein. Compared to PAH rats, mean pulmonary arterial pressure was decreased in rats at 1, 2, and 3 weeks after ADSCs-treatment (18.63 ± 2.15 mmHg versus 24.53 ± 2.90 mmHg; 23.07 ± 2.84 mmHg versus 33.18 ± 2.30 mmHg; 22.98 ± 2.34 mmHg versus 36.38 ± 3.28 mmHg, p < 0.05). Meanwhile, the right heart hypertrophy index (36.2 1 ± 4.27% versus 41.01 ± 1.29%; 39.47 ± 4.02% versus 48.75 ± 2 .13%; 41.02 ± 0.9% versus 50.52 ± 1.49%, p < 0.05, respectively), ratio of wall/lumen thickness, as well as the wall/lumen area were significantly reduced in PAH rats at these time points following ADSCs-treatment, as compared with untreated PAH rats. In summary, ADSCs may colonize the pulmonary arteries, attenuate pulmonary arterial hypertension and ameliorate pulmonary arterial remodeling..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Clinical and experimental hypertension - 37(2015), 3, Seite 241-248 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Luo, Li [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.3109/10641963.2014.954710 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1956543090 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1956543090 | ||
| 003 | DE-627 | ||
| 005 | 20230516102846.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.3109/10641963.2014.954710 |2 doi | |
| 028 | 5 | 2 | |a PQ20160617 |
| 035 | |a (DE-627)OLC1956543090 | ||
| 035 | |a (DE-599)GBVOLC1956543090 | ||
| 035 | |a (PRQ)c1830-7cc4c2128b0303a8dc3aa16a6f4da11e894807315d9479a1765de3f74e4123380 | ||
| 035 | |a (KEY)0120843820150000037000300241adiposederivedstemcellsattenuatepulmonaryarterialh | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Luo, Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adipose-derived stem cells attenuate pulmonary arterial hypertension and ameliorate pulmonary arterial remodeling in monocrotaline-induced pulmonary hypertensive rats |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Abstract We investigated the effect of adipose-derived stem cells (ADSCs) transplantation effects on structural remodeling and pulmonary artery pressure in monocrotaline (MCT)-induced pulmonary hypertensive rats. In the first experiment, 32 male Sprague-Dawley (SD) rats were randomly divided into four groups (n = 8/group): 3 ADSCs treated groups and normal control (Ctrl). ADSCs were administered through the left jugular vein at 105, 106 and 107 cells, respectively, and a cell density of 106cells/ml was shown to be optimal. The GFP-tagged ADSCs were identified in the lungs and differentiated into endothelial-like cells. In the second experiment, 96 male SD rats were randomly divided into three groups (n = 32/group): Ctrl, MCT-induced pulmonary arterial hypertension (PAH), and PAH treated with ADSCs (ADSCs). Two weeks post-MCT administration, the ADSCs group received 1 × 106 ADSCs via the external jugular vein. Compared to PAH rats, mean pulmonary arterial pressure was decreased in rats at 1, 2, and 3 weeks after ADSCs-treatment (18.63 ± 2.15 mmHg versus 24.53 ± 2.90 mmHg; 23.07 ± 2.84 mmHg versus 33.18 ± 2.30 mmHg; 22.98 ± 2.34 mmHg versus 36.38 ± 3.28 mmHg, p < 0.05). Meanwhile, the right heart hypertrophy index (36.2 1 ± 4.27% versus 41.01 ± 1.29%; 39.47 ± 4.02% versus 48.75 ± 2 .13%; 41.02 ± 0.9% versus 50.52 ± 1.49%, p < 0.05, respectively), ratio of wall/lumen thickness, as well as the wall/lumen area were significantly reduced in PAH rats at these time points following ADSCs-treatment, as compared with untreated PAH rats. In summary, ADSCs may colonize the pulmonary arteries, attenuate pulmonary arterial hypertension and ameliorate pulmonary arterial remodeling. | ||
| 540 | |a Nutzungsrecht: © 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted | ||
| 650 | 4 | |a Monocrotaline - pharmacology | |
| 650 | 4 | |a Adipose Tissue - pathology | |
| 650 | 4 | |a Hypertension, Pulmonary - therapy | |
| 650 | 4 | |a Alkaloids - pharmacology | |
| 650 | 4 | |a Stem Cell Transplantation - methods | |
| 650 | 4 | |a Pulmonary Artery - physiopathology | |
| 650 | 4 | |a Pulmonary Artery - pathology | |
| 650 | 4 | |a Hypertension, Pulmonary - etiology | |
| 650 | 4 | |a Hypertension, Pulmonary - pathology | |
| 650 | 4 | |a Hypertension, Pulmonary - physiopathology | |
| 700 | 1 | |a Lin, Taijie |4 oth | |
| 700 | 1 | |a Zheng, Suli |4 oth | |
| 700 | 1 | |a Xie, Zhenguo |4 oth | |
| 700 | 1 | |a Chen, Ming |4 oth | |
| 700 | 1 | |a Lian, Guili |4 oth | |
| 700 | 1 | |a Xu, Changsheng |4 oth | |
| 700 | 1 | |a Wang, Huajun |4 oth | |
| 700 | 1 | |a Xie, Liangdi |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental hypertension |d New York, NY : Informa Healthcare, 1978 |g 37(2015), 3, Seite 241-248 |w (DE-627)165973250 |w (DE-600)80399-6 |w (DE-576)014461706 |x 0148-3927 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2015 |g number:3 |g pages:241-248 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.3109/10641963.2014.954710 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/25271670 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.00 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 37 |j 2015 |e 3 |h 241-248 | ||